Cargando…

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer

It has been established that a high degree of tumor-infiltrating T cells is associated with ovarian cancer prognosis. We hypothesized that tumors display an immune-related program of transcription that can act in a stimulatory or a regulatory manner. We analyzed transcriptome-wide gene expression da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eng, Kevin H., Weir, Isabelle, Tsuji, Takemasa, Odunsi, Kunle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633167/ https://www.ncbi.nlm.nih.gov/pubmed/26622942

Ejemplares similares

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
por: Matsuzaki, Junko, et al.
Publicado: (2022)

Differential Antigen Expression Profile Predicts Immunoreactive Subset of Advanced Ovarian Cancers
por: Eng, Kevin H., et al.
Publicado: (2014)

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
por: Daudi, Sayeema, et al.
Publicado: (2014)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2020)

Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2013)

A rare population of tumor antigen-specific CD4(+)CD8(+) double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
por: Matsuzaki, Junko, et al.
Publicado: (2019)

Transmission of X-linked Ovarian Cancer: Characterization and Implications
por: Etter, John Lewis, et al.
Publicado: (2020)

Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
por: Want, Muzamil Yaqub, et al.
Publicado: (2019)

CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
por: Muthuswamy, Ravikumar, et al.
Publicado: (2021)

Advances in synthetic peptide immuno-regulatory epitopes
por: Creticos, Peter Socrates
Publicado: (2014)

Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4(+) but Not CD8(+) T Cell Responses against p53 in Cancer Patients and Healthy Donors
por: Tsuji, Takemasa, et al.
Publicado: (2011)

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer
por: Seagle, Brandon-Luke L., et al.
Publicado: (2016)

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
por: Amobi-McCloud, Adaobi, et al.
Publicado: (2021)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

Expression of the POTE gene family in human ovarian cancer
por: Barger, Carter J, et al.
Publicado: (2018)

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer
por: Starbuck, Kristen D., et al.
Publicado: (2018)

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8(+) T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
por: Huang, Ruea-Yea, et al.
Publicado: (2015)

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
por: Liu, Song, et al.
Publicado: (2019)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy
por: Matsuzaki, Junko, et al.
Publicado: (2015)

The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies
por: Annapragada, Ananth, et al.
Publicado: (2023)

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2015)

Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro
por: Odunsi, Kunle, et al.
Publicado: (2012)

Associations between Gene Expression Variations and Ovarian Cancer Risk Alleles Identified from Genome Wide Association Studies
por: Zhao, Hua, et al.
Publicado: (2012)

Evaluation of satisfaction with work–life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study
por: Szender, J. Brian, et al.
Publicado: (2016)

Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses
por: Matsuzaki, Junko, et al.
Publicado: (2015)

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
por: Berinstein, Neil L, et al.
Publicado: (2015)

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression
por: Barger, Carter J., et al.
Publicado: (2015)

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
por: Komorowski, Marcin P, et al.
Publicado: (2016)

Correction: Associations between Gene Expression Variations and Ovarian Cancer Risk Alleles Identified from Genome Wide Association Studies
por: Zhao, Hua, et al.
Publicado: (2013)

Predictors of Immunosuppressive Regulatory T Lymphocytes in Healthy Women
por: Hampras, Shalaka S., et al.
Publicado: (2012)

Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer
por: Harrington, Brittney S., et al.
Publicado: (2020)

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
por: Oturkar, Chetan C., et al.
Publicado: (2022)

Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages
por: Aikhionbare, Felix O, et al.
Publicado: (2007)

Whole‐exome sequencing of ovarian cancer families uncovers putative predisposition genes
por: Zhu, Qianqian, et al.
Publicado: (2019)

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8(+) T‑cells from GzmB mediated self‑destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Tcf-1 protects anti-tumor TCR-engineered CD8(+) T-cells from GzmB mediated self-destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1vkjs7h130df6o1bfefgu0p04u